Skip to main content
. 2019 Sep 23;33(6):661–671. doi: 10.1007/s40259-019-00381-2

Fig. 5.

Fig. 5

Comparison of the in vitro combination treatment with pertuzumab and SB3 or trastuzumab. Combination effect of SB3 and reference product on a HER2/HER3 heterodimerization inhibition, b apoptosis in BT474, c apoptosis in NCI-N87, and d ADCC activity in in breast cancer cell line. ADCC antibody-dependent cell-mediated cytotoxicity, D.I dimerization inhibition, HER human epidermal growth factor receptor